Clinical Characteristics of <scp>Cryopyrin‐Associated</scp> Periodic Syndrome and <scp>Long‐Term Real‐World</scp> Efficacy and Tolerability of Canakinumab in Japan: Results of a Nationwide Survey

Abstract

This study provides one of the largest epidemiologic data sets for CAPS. Although early initiation of anti-IL-1 treatment with canakinumab is beneficial for improving disease prognosis, some patients do not achieve remission despite a high serum concentration of canakinumab. Moreover, IBD may develop in CAPS after canakinumab treatment.